Pharma Taken By EU Pilot On Merging MRP/DCP Lines
This article was originally published in SRA
Executive Summary
Drug companies have shown a huge interest in part of an EU pilot project that allows them to merge licences under the mutual recognition and decentralized procedures to suit their business strategies1,2. Generic and OTC drug makers submitted over 60 applications for merging their MRP/DCP lines, of which 10 have been admitted in accordance with the maximum permissible limit of the pilot.